This site is intended for health professionals only
GlaxoSmithKline (GSK) has revealed that it is cutting its Irish workforce by 100.
The pharmaceutical group said the decision, which will affect its Cork plant, had been taken due to a falling demand for some of its top-selling drugs.
GSK moved quickly to reassure workers at the Currabinny site that the factory had a long-term future.
Finbar Whyte, vice-president and site director, said the company regretted the job cuts.
“We very much regret the impact these proposals may have on our staff and their families,” he said.
“In terms of any redundancies which may arise we will do everything we can to provide the necessary support to those impacted.
“This proposal is not a reflection on the performance of the site or the commitment of our employees.
“This proposal is necessary to protect the future of the Currabinny site which remains a key new product introduction site within GSK and, as such, has a strategic importance to GSK.”
GSK has been heavily involved in a 28 million euro investment in the country over the last few years focusing on R&D and two significant collaborations with Trinity College and University College Cork.
Copyright © PA Business 2008